[New CCR5 inhibitor antiretroviral drugs and integrase inhibitors].
Two new antiretroviral drugs belonging to a new drug family have recently been marketed in Spain. These are maraviroc (CCR5 correceptor inhibitor) and raltegravir (integrase inhibitor). These have the advantage of not presenting crossed resistance with other previously administered antiretroviral drugs, converting them into the cornerstone of the rescue treatment in the patient infected by a multiresistant viral strain. The scientific evidence available on these two drugs is reviewed in this work and its indications in the HIV infected patient are discussed.
Moreno Cuerda
V J
VJ
Servicio de Medicina Interna, Hospital de Móstoles, Móstoles, España. vjmorenocuerda@yahoo.es
Rubio García
R
R
Barros Aguado
C
C
Morales Conejo
M
M
D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes / Q000627:therapeutic use*; D023581:HIV Fusion Inhibitors / Q000627:therapeutic use*; D006801:Humans; D019429:Integrase Inhibitors / Q000627:therapeutic use*; D000077592:Maraviroc; D011760:Pyrrolidinones / Q000627:therapeutic use*; D000068898:Raltegravir Potassium; D014230:Triazoles / Q000627:therapeutic use*
D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D019429:Integrase Inhibitors; D011760:Pyrrolidinones; D014230:Triazoles; D000068898:Raltegravir Potassium; D000077592:Maraviroc